Inogen adds ‘innovation’ to CPAP market

GOLETA, Calif. – Inogen, in partnership with Yuwell, has taken another step toward becoming a comprehensive respiratory solutions company with the launch of its new Aurora line of CPAP masks. Will a CPAP device be next? 

In early January, the company introduced three masks under the Aurora brand: 

• F1 Full Face 
• N1 Nasal Cushion 
• P1 Nasal Pillows 

HME News asked Gregoire Ramade, chief commercial officer at Inogen, whether the company plans to follow up with a CPAP device. 

“We do have an internal roadmap and all I can say is, we need to start somewhere,” said Ramade, who previously spent 10 years at Philips Respironics. “We’re starting with the mask line and building on that experience to get into devices. That would be the next steps.” 

The Aurora line follows the mid-2025 debut of the Voxi 5 stationary oxygen concentrator, Inogen’s first non-portable oxygen concentrator. That product was also developed in collaboration with Yuwell, which invested about $27.2 million in Inogen in early 2025. 

Why CPAP masks? Four key drivers 

Ramade outlined four reasons for entering the CPAP market: 

• Broader positioning – CPAP masks help position Inogen as a respiratory company, not just an oxygen company. 
• Leveraging existing networks – Many pulmonology practices also offer sleep therapy, and Inogen can tap into its established referral and HME provider channels. 
• Meeting market demand – There’s a need for alternative mask options. 
• Growth opportunity – The CPAP market is one of the fastest-growing segments in the industry. 

Clinical validation and patient preference 

Inogen is emphasizing the quality of the Aurora line through a third-party, patient-preference study, Ramade says. In the study, patients compared masks from multiple manufacturers based on fit, quality and other criteria. 

“This is where the masks stood up,” he said. “They were at least as good as, if not better.” 

That validation helps position Aurora masks – whose features include a medical-grade rebound silicone cushion and a quiet honeycomb vent design – as a quality-first choice, not a low-cost alternative.  

“It’s all about delivering innovation,” Ramade said. “We want to launch products that are clinically validated and different, and are not me too.”